Alerts
Modified Hours for Memorial Day

In recognition of the upcoming Memorial Day holiday, some of The University of Kansas Health System’s offices will have modified hours on Monday, May 25.

Skip Navigation

A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma

Brief Summary

Type:
Liver

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT06050252

Study #:
STUDY00161014

Start Date:
Nov 21, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06050252

View Complete Trial Details & Eligibility at ClinicalTrials.gov